Study reveals new factor involved in controlling calorie expenditure
November 25, 2024 / Neuropeptide Y Metabolism / Obesity Treatment / Brown Adipose Tissue Activation
Researchers discovered a new component in the peripheral nervous system where neuropeptide Y (NPY) enhances metabolism and thermogenesis, offering potential for novel obesity treatments by targeting fat-burning mechanisms instead of appetite regulation.
GLP-1RA Dispensing Trends Indicate Shifting Landscape in Obesity Treatment
November 25, 2024 / GLP-1RA Obesity Treatment Trends / Pharmacologic Obesity Management / Bariatric Surgery / Semaglutide and Liraglutide Usage / Obesity Treatment
GLP-1 receptor agonist (GLP-1RA) prescriptions for obesity management increased by 132.6% between 2022 and 2023, coinciding with a 25.6% decline in bariatric surgeries. GLP-1RAs may be shifting obesity treatment trends toward pharmacologic options.
Scientists Uncover Liver-Brain Link That Could Reverse Night Shift Weight Gain
November 25, 2024 / Liver-brain Circadian Link / Weight Gain Solution / ddVagus Nerve Eating Regulation / Metabolic Disorder Cicadian Therapys
Researchers discovered a liver-brain communication pathway via the vagus nerve that regulates eating patterns. Disrupted circadian rhythms can lead to overeating and weight gain, but targeting this pathway offers potential for managing metabolic disorders in shift workers.
ASPP2 deficiency promotes the progression of metabolic dysfunction-associated steatohepatitis via ACSL4 upregulation
November 25, 2024 / ASPP2 / MASH Progression / Fatty Liver Disease / MASH Therapeutic Targets / Liver Inflammation / Lipid Accumulation / MAFLD
ASPP2 deficiency accelerates MASH progression by upregulating ACSL4, leading to increased lipid accumulation, inflammation, and impaired mitochondrial function. Targeting the ASPP2-ACSL4 pathway offers a potential therapeutic strategy for metabolic dysfunction-associated steatohepatitis.
Semaglutide shows liver benefits in Phase 3 MASH trial
November 25, 2024 / Semaglutide MASH Treatment / Liver Fibrosis Reduction / GLP-1 Receptior / Clinical Trial
Semaglutide, a GLP-1 receptor agonist, significantly reduced liver fat and scarring in adults with MASH, showing improved liver outcomes after 1.5 years in the Phase 3 ESSENCE trial. Semaglutide offers potential for treating this advanced liver disease.
Advantage Therapeutics Inc. Announces Formation of Klothea Bio, Inc. to Advance Research and Development of Klotho Protein for Age-Related Therapeutics
November 25, 2024 / Klotho Protein Therapy / Anti-aging mRNA Treatments / Longevity Reasearch Klothea Bio / Age-related Disease Prevention
Klothea Bio, a subsidiary of Advantage Therapeutics, focuses on Klotho protein therapies for age-related diseases. Using mRNA technology, it aims to restore Klotho levels, potentially preventing conditions like Alzheimer’s, obesity, and metabolic syndrome while enhancing healthspan and lifespan.
Groundbreaking research sheds light on mitochondrial DNA depletion syndrome
November 25, 2024 / Mitochondrial DNA Depletion Syndrome / MICOS10 Gene Variants / Hepatocerebral Mitochondrial Disease
Researchers identified MICOS10 variants as key contributors to mitochondrial DNA depletion syndrome (MTDPS), highlighting their role in mitochondrial dysfunction and cristae abnormalities. Restoring MICOS10 improved mitochondrial respiration, offering hope for targeted diagnostics and therapies for this rare genetic disorder.
The pattern of diabetic care and glycemic control among the ambulatory diabetic patients in tertiary care settings in Bangladesh
November 25, 2024 / Uncontrolled Diabetes / Bangladesh / Diabetic Care / Glycemic Control Risk Factors / Hyperlipidemia / Diabetes
A study in Bangladesh revealed that 68.6% of ambulatory diabetic patients had uncontrolled diabetes. Contributing factors included hyperlipidemia, long disease duration, and poor dietary habits. Emphasizing routine monitoring and lifestyle modifications is essential for improved diabetes management.
Weight Loss Breakthrough: Scientists Discover Natural Compound That Suppresses Appetite
November 23, 2024 / Japan / Physical Activity / Metabolic Syndrome
A study identified key factors influencing exercise habit acquisition in middle-aged workers, including advanced behavioral change stages, high physical activity, and healthy HDL levels, while heavy alcohol consumption negatively impacted habit formation. Insights may enhance health guidance programs.
Probiotics shown to mitigate effects of toxic fire-retardant chemicals
November 23, 2024 / PBDE Exposure and Probiotics / Limosilactobacillus Reuteri Benefits / Fire-retardant Chemical Health Effects / Gut Microbiome and PBDE Mitigation
Probiotic Limosilactobacillus reuteri supplementation during pregnancy mitigates the adverse neurodevelopmental, behavioral, and metabolic effects of fire-retardant PBDE exposure in mice. The study highlights probiotics’ potential to reduce pollutant-related health risks in vulnerable populations.
Pathogenic role of acyl coenzyme A binding protein (ACBP) in Cushing’s syndrome
November 22, 2024 / ACBP Cushing’s Syndrome / Metabolic Dysfunction in Cushing’s / ACBP/DBI Therapeutic Targeting / Metabolic Effects / Thyroid Hormone
Elevated ACBP/DBI levels contribute to Cushing’s syndrome by promoting metabolic dysfunction, including increased food intake and adiposity. Targeting ACBP/DBI through gene knockout, antibodies, or thyroid hormone modulation mitigates these effects, highlighting it as a therapeutic target for treatment.
Metabolic and bariatric surgery safe and effective for patients with severe obesity
November 21, 2024 / Bariatric Surgery Safety / Severe Obesity Treatment / Metabolic Surgery
Metabolic and bariatric surgery is safe and effective for patients with severe obesity (BMI ≥ 70), with a low 30-day complication rate of 0.7%. Patients demonstrated robust weight loss and durable outcomes up to one year post-surgery.
Groundbreaking new drug successfully reduces weight and cholesterol levels
November 21, 2024 / Nanogel Obesity Treatment / Liver-specific Drug Delivery / Metabolic Disease
Nanogels delivering thyromimetic axitirome to liver cells reversed weight gain, normalized cholesterol, and reduced liver inflammation in mice without side effects. This targeted approach may revolutionize obesity and metabolic disease treatment by enhancing fat oxidation and metabolism.
China-based biotech startup Laekna teams up with Eli Lilly to develop obesity treatment
November 21, 2024 / ActRIIA Obesity Treatment / ddObesity Therapy / Lean Mass Obesity Drug
Laekna and Eli Lilly are collaborating to develop LAE102, an innovative ActRIIA monoclonal antibody targeting obesity. The partnership integrates Laekna’s novel approach with Lilly’s expertise to advance obesity treatment, focusing on improving lean mass and reducing fat mass.
Cardiovascular Disease Affects Patients With CKD Up to 28 Years Earlier
November 20, 2024 / CKD Cardiovascular Risk / Type 2 Diabetes and CVD / Chronic Kidney Disease Prevention
Chronic kidney disease (CKD) and type 2 diabetes accelerate cardiovascular disease (CVD) risk by 8-28 years, with patients experiencing heightened risk as early as their 30s. Early detection of CKM syndrome components is crucial for optimizing prevention strategies.
Memories of obesity can linger in fat cells long after weight loss
November 19, 2024 / Obesity Memory in Fat Cells / Weight Loss / Fat Cell Transcriptional Changes / Obesity Treatment
Adipose tissue retains epigenetic and transcriptional changes after weight loss, creating an “”obesity memory”” that predisposes individuals to weight regain. These findings may guide future interventions to disrupt this memory and improve obesity treatment outcomes.
Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
November 19, 2024 / VK2809 NASH/MASH Treatment / Liver Fat Reduction Therapy / Fibrosis Improvement / Cardioprotective Metabolic Drug
Viking Therapeutics’ VK2809 significantly reduced liver fat, resolved NASH/MASH, improved fibrosis, and lowered plasma lipids in a Phase 2b study. With excellent tolerability, VK2809 offers promise as a safe, effective treatment for metabolic liver diseases.
ESSENCE Phase 3 trial results demonstrating statistically significant and superior improvements with semaglutide 2.4 mg in people with MASH presented at AASLD 2024 – The Liver Meeting®
November 19, 2024 / Semaglutide MASH Phase 3 Trial / MASH Liver Fibrosis Treatment / Metabolic Liver Disease / Cardiometabolic Benefits in MASH
The ESSENCE Phase 3 trial demonstrated semaglutide 2.4 mg significantly improved liver fibrosis and resolved steatohepatitis in MASH patients. With secondary benefits like improved liver enzyme levels, semaglutide shows promise for managing advanced liver disease and cardiometabolic conditions.
Monthly efimosfermin offers ‘rapid, meaningful’ improvement for MASH, related fibrosis
November 19, 2024 / Efimosfermin MASH Treatment / Liver Therapy / Fibrosis Improvement in MASH / Metabolic Health in Liver Disease / Anti-fibrotic MASH Therapy
Monthly efimosfermin significantly improved MASH resolution and fibrosis at 24 weeks, with 45.2% achieving fibrosis improvement and 67.7% resolving MASH without worsening fibrosis. This FGF21 analogue offers potential as a targeted, convenient anti-fibrotic therapy for MASH.